Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974349 | 0.78 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL14308095 | 0.78 | TRPV1 (0.42) | TRPV1METAP2SCN5ASCN9A | |
| SCHEMBL4357729 | 0.78 | TRPV1 (0.58) | TRPV1KDM4E | |
| SCHEMBL4973903 | 0.77 | TRPV1 (0.52) | TRPV1KDM4EMETAP2SCN5ASCN9A | |
| SCHEMBL4360226 | 0.75 | TRPV1 (0.69) | TRPV1SCN5ASCN9A | |
| SCHEMBL4973901 | 0.75 | TRPV1 (0.55) | TRPV1KDM4ESCN9A | |
| SCHEMBL27600476 | 0.75 | TRPV1 (0.55) | TRPV1METAP2 | |
| SCHEMBL11453577 | 0.74 | KDM4E (0.46) | KDM4E | |
| SCHEMBL5479649 | 0.74 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL4908519 | 0.74 | TRPV1 (0.68) | TRPV1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070191374-A1 | Substituted cinnolin-4-ylamines | NEUROGEN COROPERATION (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070191374-A1 | Substituted cinnolin-4-ylamines | NEUROGEN COROPERATION (US) | 2007-08-16 | — | — | US | disclosed |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | US | disclosed |
| US-7074799-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | TRPV1 244/4885KDM4E 2662/4885PARP1 3763/4885 |
| US-20070191374-A1 | Substituted cinnolin-4-ylamines | CNR1, GPR174, CNR2 | TRPV1 379/4885KDM4E 3499/4885PARP1 3260/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885KDM4E 4717/4885PARP1 2871/4885 |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 297/4885KDM4E 2859/4885PARP1 3630/4885 |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 244/4885KDM4E 2662/4885PARP1 3763/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 240/4885KDM4E 3001/4885PARP1 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.